Table 2.
Unadjusted outcomes 30 days after cardiac implantable electronic device implantation by oral anticoagulation strategy
| Warfarin | NOAC | |||||||
|---|---|---|---|---|---|---|---|---|
| Overall | Uninterrupted | Interrupted | Overall | Uninterrupted | Interrupted | |||
| Bridging | No Bridging | Bridging | No Bridging | |||||
| No. | 284 | 101 | 33 | 150 | 60 | 21 | 4 | 35 |
| Major bleeding | 1 (0.4%) | 0 (0%) | 1 (3.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Stroke/TIA | 3 (1.1%) | 1 (1.0%) | 1 (3.0%) | 1 (0.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| All‐cause hospitalization | 18 (6.3%) | 4 (4.0%) | 4 (12.1%) | 10 (6.7%) | 3 (5.0%) | 1 (4.7%) | 1 (25.0%) | 1 (2.9%) |
| Cardiovascular hospitalization | 12 (4.2%) | 2 (2.0%) | 3 (9.1%) | 7 (4.7%) | 1 (1.6%) | 0 (0.0%) | 0 (0.0%) | 1 (2.9%) |
| Bleeding hospitalization | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.6%) | 0 (0.0%) | 0 (0.0%) | 1 (2.9%) |
Abbreviations: NOAC, non–vitamin K antagonist oral anticoagulants; TIA, transient ischemic attack.
Values are reported as number with percentage of total patients experiencing adverse event in parenthesis.